A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT02500407 · COMPLETED

Trial details

NCT number: NCT02500407
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lymphocytic Leukemia, Chronic Lymphoma, Non Hodgkin

Start date: 2015-09-15
Primary completion: 2024-05-21
Enrollment: 713

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.